Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease

Neurobiol Aging. 2009 Mar;30(3):501-2. doi: 10.1016/j.neurobiolaging.2007.07.010. Epub 2007 Aug 27.

Abstract

Alzheimer's disease (AD) pathology has been described in Parkinson's disease (PD) patients with leucine-rich repeat kinase-2 (LRRK2) mutations. A common LRRK2 Gly2385Arg variant has been widely shown to be associated with a twofold increased risk of PD in various Asian populations. In a case control study, the frequency of the heterozygous Gly2385Arg genotype was demonstrated in 4.3% of AD compared to 4.5% in controls (odds ratio=0.94, 95% CI 0.37-2.42, p=1.0). The Gly2385Arg variant does not appear to modulate the risk of AD in our population.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / genetics*
  • Amino Acid Substitution / genetics*
  • Arginine / genetics*
  • Case-Control Studies
  • Female
  • Genetic Carrier Screening
  • Genetic Variation / genetics
  • Glycine / genetics*
  • Humans
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Male
  • Middle Aged
  • Mutation / genetics
  • Protein-Serine-Threonine Kinases / genetics*
  • Risk Factors

Substances

  • Arginine
  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Protein-Serine-Threonine Kinases
  • Glycine